| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2337/DIACARE.27.2.596 |
| P698 | PubMed publication ID | 14747245 |
| P50 | author | American Psychiatric Association | Q466524 |
| American Diabetes Association | Q4743610 | ||
| American Association of Clinical Endocrinology | Q18148801 | ||
| North American Association for the Study of Obesity | Q115272844 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obesity | Q12174 |
| P304 | page(s) | 596-601 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Consensus development conference on antipsychotic drugs and obesity and diabetes. | |
| P478 | volume | 27 |
| Q37719385 | 759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment |
| Q47182118 | A 12-week weight reduction intervention for overweight individuals taking antipsychotic medications |
| Q36989599 | A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone |
| Q35833294 | A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder |
| Q34174609 | A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting |
| Q45996927 | A Doctor is in the House: Stakeholder Focus Groups About Expanded Scope of Practice of Community Psychiatrists. |
| Q34035818 | A Long Time Coming - The Creation of an Evidence Base for Physical Activity Prescription to Improve Health Outcomes in Bipolar Disorder |
| Q40809582 | A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications |
| Q37299884 | A Randomized, Double-blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Major Depressive Disorder |
| Q37427104 | A UK audit of screening for the metabolic side effects of antipsychotics in community patients |
| Q36853249 | A case series: evaluation of the metabolic safety of aripiprazole |
| Q46766527 | A crossover study on lipid and weight changes associated with olanzapine and risperidone |
| Q46505295 | A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic |
| Q38660754 | A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice |
| Q35185643 | A pilot evaluation of the In SHAPE individualized health promotion intervention for adults with mental illness |
| Q46798727 | A prospective study of glycaemic status in anti-psychotic-treated patients |
| Q34598760 | A randomized crossover, pilot study examining the effects of a normal protein vs. high protein breakfast on food cravings and reward signals in overweight/obese "breakfast skipping", late-adolescent girls |
| Q37172973 | A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) |
| Q37562207 | A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder |
| Q36199687 | A review of pharmacologic strategies for switching to atypical antipsychotics |
| Q47409717 | A small group aerobic exercise programme that reduces body weight is feasible in adults with severe chronic schizophrenia: a pilot study |
| Q23915528 | A walking program for outpatients in psychiatric rehabilitation: pilot study |
| Q34421981 | A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study |
| Q38176569 | Acute hyperglycemia associated with short-term use of atypical antipsychotic medications |
| Q35062633 | Acute psychosis and type 2 diabetes mellitus:should screening guidelines be revised? |
| Q36649096 | Acute treatment of mania: an update on new medications |
| Q35189111 | Adapting SugarWatch to manage metabolic syndrome in a partial hospitalization program: a feasibility study |
| Q37183591 | Addressing cardiometabolic risk during treatment with antipsychotic medications |
| Q33998049 | Addressing prediabetes in childhood obesity treatment programs: support from research and current practice |
| Q38941350 | Adherence to evidence-based treatment guidelines for bipolar depression in an inpatient setting. |
| Q79998509 | Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients |
| Q37783298 | Adjunctive Use of Atypical Antipsychotics for Treatment‐Resistant Generalized Anxiety Disorder |
| Q90980284 | Advancing regulatory science and assessment of FDA REMS programs: A mixed-methods evaluation examining physician survey response |
| Q34583643 | Adverse effects of atypical antipsychotics : differential risk and clinical implications |
| Q34614432 | Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. |
| Q42944964 | American Diabetes Association Postgraduate Meetings--2011. |
| Q60472752 | An Examination of Adults on Antipsychotic Medication at Risk for Metabolic Syndrome: A Comparison with Obese and Eating Disorder Populations |
| Q47629240 | An Investigation of Cardiovascular Risks in a Group of Children and Adolescents Who Use Atypical Antipsychotics |
| Q87059221 | An acute rat in vivo screening model to predict compounds that alter blood glucose and/or insulin regulation |
| Q37062558 | An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia |
| Q42905755 | An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study |
| Q38184482 | An update on medication management of behavioral disorders in autism |
| Q34345246 | Anti-psychotic prescription pattern: A preliminary survey of Psychiatrists in India |
| Q36706808 | Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. |
| Q41488659 | Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System |
| Q89768216 | Antipsychotic Use in the Prevention and Treatment of Intensive Care Unit Delirium in Pediatric Patients |
| Q35892369 | Antipsychotic drugs and risk of type 2 diabetes: an evidence-based approach |
| Q40201163 | Antipsychotic drugs as a risk factor for venous thromboembolism |
| Q34659096 | Antipsychotic drugs for first-episode schizophrenia: a comparative review |
| Q37039179 | Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study |
| Q37160453 | Antipsychotic induced weight gain in schizophrenia:mechanisms and management |
| Q40386583 | Antipsychotic prescribing for behavioral disorders in US youth: physician specialty, insurance coverage, and complex regimens |
| Q24235450 | Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems |
| Q24244736 | Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems |
| Q36852489 | Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis |
| Q34661651 | Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients |
| Q36784527 | Are second generation antipsychotics a distinct class? |
| Q34121832 | Aripiprazole for late-life schizophrenia |
| Q46886132 | Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study |
| Q35684487 | Aripiprazole versus haloperidol treatment in early-stage schizophrenia |
| Q34333899 | Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder |
| Q34558285 | Aripiprazole: pharmacology, efficacy, safety and tolerability |
| Q33160123 | Assessing QT interval prolongation and its associated risks with antipsychotics. |
| Q28088782 | Assessment and management of behavioral and psychological symptoms of dementia |
| Q45917629 | Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. |
| Q46949691 | Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design |
| Q93065943 | Association Between Antipsychotic Medication Use and Diabetes |
| Q84969914 | Association Between Antipsychotics and Body Mass Index When Treating Patients with Tics |
| Q47605999 | Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta-analysis. |
| Q34101759 | Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? |
| Q35460642 | Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). |
| Q36141743 | Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons |
| Q37201683 | Association of metabolic syndrome with schizophrenia |
| Q36804310 | Associations Between Gender and Obesity Among Adults with Mental Illnesses in a Community Health Screening Study |
| Q45904529 | Attention to body mass index by child psychiatry providers when prescribing second-generation antipsychotic medication to children: a survey study using a clinical vignette. |
| Q22241426 | Atypical Antipsychotics in Children with Pervasive Developmental Disorders |
| Q36299999 | Atypical antipsychotic drugs, diabetes and ethnicity |
| Q37058188 | Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities |
| Q37781370 | Atypical antipsychotic tolerability and switching strategies in bipolar disorder |
| Q34006864 | Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles |
| Q37963571 | Atypical antipsychotic-induced weight gain: insights into mechanisms of action |
| Q33928935 | Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications |
| Q36302677 | Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring |
| Q38448948 | Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations |
| Q39304810 | Atypical antipsychotics such as risperidone, but not paliperidone, worsen vascular endothelial function via upregulation of adhesion molecules VCAM-1, ICAM-1, and E-selectin in diabetic rats |
| Q89329442 | Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects |
| Q34330761 | Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature |
| Q47925621 | BMI independently relates to glycaemia in patients with severe enduring mental illness (SMI). |
| Q36970128 | Balancing efficacy and safety in treatment with antipsychotics. |
| Q33677790 | Bariatric endocrinology: principles of medical practice. |
| Q34900812 | Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth. |
| Q24197824 | Behavioural interventions for reducing weight gain in schizophrenia |
| Q38220364 | Belgian consensus on metabolic problems associated with atypical antipsychotics |
| Q38808576 | Bipolar depression: Managing patients with second generation antipsychotics |
| Q35236988 | Bipolar depression: trial-based insights to guide patient care. |
| Q37207249 | Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden |
| Q37889502 | Bipolar disorder and weight gain: a multifactorial assessment |
| Q37110231 | Bipolar-I patient characteristics associated with differences in antimanic medication prescribing. |
| Q51887291 | Body composition in psychotic disorders: a general population survey. |
| Q35100107 | Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate |
| Q46517339 | Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia |
| Q51897378 | Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. |
| Q45946784 | Bodyweight in patients with idiopathic gastroparesis: roles of symptoms, caloric intake, physical activity, and body metabolism. |
| Q34002900 | Branch retinal vein occlusion associated with quetiapine fumarate |
| Q43951943 | Brazilian Consensus on second-generation antipsychotics and metabolic disorders |
| Q35247085 | Can metformin undo weight gain induced by antipsychotics? |
| Q37635208 | Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis |
| Q47659434 | Cardiometabolic effects of psychotropic medications. |
| Q89329899 | Cardiometabolic management in severe mental illness requiring an atypical antipsychotic |
| Q34613195 | Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents |
| Q40400512 | Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD. |
| Q37788533 | Cardiovascular aspects of antipsychotics |
| Q51871881 | Cardiovascular disease and diabetes in people with severe mental illness. |
| Q37413163 | Cardiovascular effects of noncardiovascular drugs |
| Q51899814 | Cardiovascular health in patients with serious mental illnesses: we need to do more. |
| Q38644789 | Cardiovascular risk screening for individuals with serious mental illness |
| Q41853522 | Challenges for policy makers and organizational leaders: addressing trends in mental health inequalities |
| Q51924288 | Challenges in advancing mental and physical health of patients with serious mental illness. |
| Q35574462 | Change in framingham risk score in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, 6-week trial of ziprasidone and olanzapine |
| Q36201085 | Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory |
| Q28728401 | Changes in body weight and psychotropic drugs: a systematic synthesis of the literature |
| Q50546113 | Changes in metabolic parameters in patients with severe mental illness over a 10-year period: A retrospective cohort study. |
| Q37161980 | Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine |
| Q37626797 | Changes in physician antipsychotic prescribing preferences, 2002-2007. |
| Q48321579 | Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy. |
| Q35641776 | Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics |
| Q34084157 | Childhood bipolar disorder: a clinical vignette |
| Q47946228 | Childhood predictors of antipsychotic use among young people in Finland |
| Q34432313 | Cholesterol, mood, and vascular health: Untangling the relationship: Does low cholesterol predispose to depression and suicide, or vice versa? |
| Q30477036 | Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance |
| Q37322237 | Classifying antipsychotic agents : need for new terminology |
| Q38584852 | Clinical management of comorbid diabetes and psychotic disorders |
| Q46098816 | Clozapine-associated weight loss |
| Q39363953 | Clozapine-induced hyperlipidemia resolved after switch to aripiprazole therapy |
| Q35008098 | Co-occurring depressive symptoms in the older patient with schizophrenia |
| Q34646095 | Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization |
| Q90051846 | Comparison of risperidone, olanzapine and quetiapine: effects on body weight, serum blood glucose and prolactin |
| Q40336391 | Compliance of psychotropic drug prescription with clinical practice guidelines in older inpatients |
| Q38283039 | Concomitant Use of Topiramate Inducing Neutropenia in a Schizophrenic Male Stabilized on Clozapine |
| Q49885361 | Consequences of Undocumented Medication Use. |
| Q44049223 | Considerations for inpatient versus outpatient treatment with antipsychotics. |
| Q88581527 | Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes |
| Q49917593 | Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia |
| Q36488206 | Current schizophrenia drugs: efficacy and side effects |
| Q79858778 | Decreased serum activity of semicarbazide-sensitive amine oxidase (SSAO) in patients treated with second generation antipsychotics: a link to impaired glucose metabolism? |
| Q59938420 | Des recommandations probantes pour surveiller l’innocuité des antipsychotiques de deuxième génération chez les enfants et les adolescents |
| Q26864342 | Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate? |
| Q45059806 | Development of Collaborative Drug Therapy Management and Clinical Pharmacy Services in an Outpatient Psychiatric Clinic |
| Q37613388 | Development of diabetes mellitus associated with quetiapine: A case series. |
| Q36777672 | Diabetes Screening Among Underserved Adults With Severe Mental Illness Who Take Antipsychotic Medications |
| Q46642105 | Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study |
| Q38826676 | Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review |
| Q35352490 | Diabetes and psychiatric disorders |
| Q36310303 | Diabetes and schizophrenia 2005: are we any closer to understanding the link? |
| Q46945909 | Diabetes associated with atypical antipsychotic treatment may be severe but reversible: case report |
| Q43801260 | Diabetes care and mental illness: the social organization of food in a residential care facility. |
| Q34574728 | Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment |
| Q38274901 | Diabetes mellitus and severe mental illness: mechanisms and clinical implications. |
| Q53698117 | Diabetic ketoacidosis and severe hypertriglyceridaemia as a consequence of an atypical antipsychotic agent. |
| Q46408003 | Diabetic ketoacidosis associated with aripiprazole |
| Q98947044 | Diabetic retinopathy screening in persons with mental illness: a literature review |
| Q37407146 | Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature |
| Q24203991 | Dietary advice for schizophrenia |
| Q52668969 | Differences in BMI between Mexican and Colombian patients receiving antipsychotics: results from the International Study of Latinos on Antipsychotics (ISLA). |
| Q39436079 | Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation |
| Q48480681 | Differential pharmacology of atypical antipsychotics: clinical implications |
| Q39150793 | Discontinuation of somatic medication during psychiatric hospitalization |
| Q34254903 | Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study |
| Q36310323 | Do guidelines for severe mental illness promote physical health and well-being? |
| Q35984024 | Does a Physician's Attitude toward a Patient with Mental Illness Affect Clinical Management of Diabetes? Results from a Mixed-Method Study |
| Q35529149 | Does colocated care improve access to cardiometabolic screening for patients with serious mental illness? |
| Q52652401 | Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. |
| Q36367159 | Dopamine synthesis and D3 receptor activation in pancreatic β-cells regulates insulin secretion and intracellular [Ca(2+)] oscillations |
| Q37844574 | Drug safety evaluation of ziprasidone |
| Q42805312 | Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics |
| Q22306015 | Drug-induced diabetes mellitus |
| Q36753691 | Drug-induced endocrine and metabolic disorders |
| Q39404106 | Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options |
| Q37681620 | Dyslipidaemia and Medical Outcome (Health Related Quality of Life) in Patients with Schizophrenia Taking Antipsychotics in Enugu, Nigeria. |
| Q45942751 | Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats. |
| Q37996445 | Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: a systematic review |
| Q39164849 | Effectiveness of an educational handbook in improving psychiatry resident knowledge of second-generation antipsychotics |
| Q42162953 | Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial |
| Q36241602 | Effects of auricular acupressure on body weight parameters in patients with chronic schizophrenia |
| Q34665858 | Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers |
| Q47316994 | Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. |
| Q47554150 | Effects of primary care clinician beliefs and perceived organizational facilitators on the delivery of preventive care to individuals with mental illnesses. |
| Q35191252 | Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study |
| Q41733975 | Effects of weight loss diet therapy on anthropometric measurements and biochemical variables in schizophrenic patients. |
| Q37299902 | Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia |
| Q89113846 | Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews |
| Q34791688 | Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study |
| Q34092254 | Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies |
| Q37118263 | Efficacy of add-on topiramate therapy in psychiatric patients with weight gain |
| Q37710237 | Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain |
| Q34707472 | Elderly patients with schizophrenia and depression: diagnosis and treatment |
| Q37218782 | Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder |
| Q38193790 | Emerging role of aripiprazole for treatment of irritability associated with autistic disorder in children and adolescents |
| Q50072523 | Enhancing metabolic monitoring for children and adolescents using second-generation antipsychotics |
| Q37162718 | Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia |
| Q37270950 | Evaluating the association between clozapine and venous thromboembolism |
| Q38742311 | Evaluation of antidiabetic activity of biologically synthesized silver nanoparticles using Pouteria sapota in streptozotocin-induced diabetic rats. |
| Q37691001 | Evaluation of monitoring for metabolic effects in children treated with second generation antipsychotics in a pediatric clinic |
| Q89329550 | Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review |
| Q44451644 | Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations |
| Q36873932 | Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disorders |
| Q35128405 | Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth |
| Q35572650 | Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. |
| Q36822176 | Evidence-based treatment of delirium in patients with cancer |
| Q51823658 | Excess mortality from chronic physical disease in psychiatric patients-the forgotten problem. |
| Q33256430 | Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report |
| Q37091453 | Exercise program adherence using a 5-kilometer (5K) event as an achievable goal in people with schizophrenia |
| Q50096809 | Exploring the Relationship Between Body Mass Index and Positive Symptom Severity in Persons at Clinical High Risk for Psychosis |
| Q35334500 | Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders |
| Q45771183 | Factors influencing cardiometabolic monitoring practices in an adult community mental health service |
| Q33845881 | First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents |
| Q44687862 | First-episode affective psychosis and lipid monitoring: survival analysis of the first abnormal lipid test |
| Q33488312 | Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data |
| Q34611306 | Focus on aripiprazole: a review of its use in child and adolescent psychiatry |
| Q36974977 | Focus on ziprasidone: a review of its use in child and adolescent psychiatry |
| Q64039164 | From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone |
| Q36060797 | Gender and race disparities in weight gain among offenders prescribed antidepressant and antipsychotic medications |
| Q40982860 | Gender differences in antipsychotics prescribed to veterans with serious mental illness |
| Q40549171 | Gender differences in mood stabilizer medications prescribed to Veterans with serious mental illness |
| Q37661867 | Gene-specific DNA methylation may mediate atypical antipsychotic-induced insulin resistance. |
| Q33257886 | Genetics of antipsychotic treatment emergent weight gain in schizophrenia |
| Q38674162 | Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases |
| Q40963710 | Glucose Disturbances and Atypical Antipsychotic Use in the Intensive Care Unit |
| Q58739865 | Glucose and Prolactin Monitoring in Children and Adolescents Initiating Antipsychotic Therapy |
| Q34631699 | Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. |
| Q41279177 | Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation |
| Q34334535 | Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials |
| Q33902893 | High prevalence of diabetes and pre-diabetes in adults with Williams syndrome |
| Q37535043 | How quickly do physicians adopt new drugs? The case of second-generation antipsychotics |
| Q39751540 | Hyperosmolar hyperglycemic state in a patient taking risperidone |
| Q34143459 | Hyperprolactinemia with Antipsychotic Drugs in Children and Adolescents |
| Q45134279 | Hypertriglyceridemia in a Pediatric Referral Practice: Experience With 300 Patients |
| Q24672914 | Hypertriglyceridemia: its etiology, effects and treatment |
| Q55514878 | IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis. |
| Q47702575 | Impact of Coordinated Behavioral Health Management on Quality Measures of Antipsychotic Use. |
| Q47627065 | Impact of a Mental Health Based Primary Care Program on Quality of Physical Health Care. |
| Q38904115 | Impact of a nurse practitioner role on metabolic monitoring completion and referrals for consumers admitted to the intensive care area of an acute inpatient psychiatric unit. |
| Q28261086 | Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery |
| Q37128936 | Impact of medical comorbidity on medication management of schizophrenia. |
| Q53159774 | Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. |
| Q47581724 | Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder |
| Q34325802 | Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors |
| Q46074998 | Improvement of metabolic risk profile under second-generation antipsychotics: a pilot intervention study |
| Q47625146 | Improving Ambulatory Care Resident Training: Preparing for Opportunities to Treat Mental Illness in the Primary Care Setting. |
| Q38743975 | Improving Cardiometabolic Monitoring of Children on Antipsychotics |
| Q35547018 | Improving dietary and physical activity practices in group homes serving residents with severe mental illness |
| Q34139645 | Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, Canada |
| Q37354917 | Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods |
| Q91360526 | Improving monitoring for metabolic syndrome using audit |
| Q33704267 | Improving quality and diffusing best practices: the case of schizophrenia |
| Q34086096 | Incident somatic comorbidity after psychosis: results from a retrospective cohort study based on Flemish general practice data |
| Q35237063 | Incomplete response in late-life depression: getting to remission |
| Q46778035 | Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients |
| Q34183475 | Inequalities in healthcare provision for people with severe mental illness |
| Q51901947 | Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population. |
| Q33891235 | Institutional policy changes aimed at addressing obesity among mental health clients. |
| Q46374431 | Integrated Medicine and Psychiatry Curriculum for Psychiatry Residency Training: a Model Designed to Meet Growing Mental Health Workforce Needs |
| Q23915525 | Integrated primary and mental health care: evaluating a nurse-managed center for clients with serious and persistent mental illness |
| Q47155489 | Interleukin-6 in Schizophrenia-Is There a Therapeutic Relevance? |
| Q37940519 | International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia |
| Q53006399 | Interpreting the efficacy findings in the CATIE study: what clinicians should know. |
| Q24243093 | Interventions to reduce weight gain in schizophrenia |
| Q51912991 | Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. |
| Q47213104 | Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain |
| Q38226897 | Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies |
| Q39158338 | Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics? |
| Q36804059 | Is antipsychotic medication stigmatizing for people with mental illness? |
| Q33972014 | Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study |
| Q37044422 | Is schizophrenia a syndrome of accelerated aging? |
| Q37073680 | Issues in co-morbid severe mental illnesses in HIV infected individuals |
| Q42120078 | Lack of tolerable treatment options for patients with schizophrenia |
| Q34056408 | Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents |
| Q38066118 | Lipid effects of psychiatric medications |
| Q36895534 | Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives |
| Q46689239 | Long-acting risperidone in stable patients with schizoaffective disorder |
| Q47279555 | Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone |
| Q37178608 | Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. |
| Q50562102 | Long-term mortality of persons with severe mental illness and diabetes: a population-based cohort study in Denmark. |
| Q36545075 | Long-term use of atypical antipsychotics in bipolar disorder |
| Q37456318 | Longitudinal racial/ethnic disparities in antimanic medication use in bipolar-I disorder |
| Q36987106 | Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness. |
| Q22241943 | Management of Obesity in Adults: European Clinical Practice Guidelines |
| Q46902584 | Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme |
| Q34983478 | Management of atypical antipsychotic drug-induced weight gain: focus on metformin |
| Q37439921 | Management of common psychiatric conditions in the HIV-positive population. |
| Q37423313 | Management of patients presenting with acute psychotic episodes of schizophrenia. |
| Q42974032 | Management of physical health in patients with schizophrenia: international insights. |
| Q36639919 | Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials |
| Q36016688 | Managing bipolar disorder in the elderly: defining the role of the newer agents |
| Q37623789 | Managing weight in persons living with severe mental illness in community settings: a review of strategies used in community interventions |
| Q90101980 | Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis |
| Q37883895 | Mechanisms and genetics of antipsychotic-associated weight gain |
| Q36248058 | Mechanistic connections between glucose/lipid disturbances and weight gain induced by antipsychotic drugs |
| Q50579396 | Medication Discontinuation in Patients After Discharge From a Psychiatric Hospital. |
| Q37672506 | Medication adherence and glycemic control in patients with psychotic disorders in the Veterans Affairs healthcare system |
| Q30276191 | Medication-induced diabetes mellitus |
| Q37687952 | Mental Health Consumer Experiences and Strategies When Seeking Physical Health Care: A Focus Group Study |
| Q38981510 | Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve patients with nonaffective psychosis |
| Q36997233 | Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents |
| Q55025268 | Metabolic Syndrome in First Episode Schizophrenia, Based on the National Mental Health Registry of Schizophrenia (NMHR) in a General Hospital in Malaysia: A 10-Year Retrospective Cohort Study. |
| Q36474147 | Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective |
| Q33935882 | Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study |
| Q37496873 | Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients |
| Q46152573 | Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. |
| Q36161851 | Metabolic investigation in psychiatric disorders |
| Q26783003 | Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management |
| Q36577861 | Metabolic monitoring for patients treated with antipsychotic medications |
| Q89329588 | Metabolic monitoring in children 5 years of age and younger prescribed second-generation antipsychotic medications |
| Q38006525 | Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotic-treated children. |
| Q51399602 | Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics. |
| Q51391762 | Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone |
| Q33236751 | Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre |
| Q37383679 | Metabolic risks in older adults receiving second-generation antipsychotic medication |
| Q37189197 | Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes |
| Q36310316 | Metabolic syndrome and cardiovascular disease |
| Q50551373 | Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden. |
| Q37738743 | Metabolic syndrome associated with schizophrenia and atypical antipsychotics |
| Q35793800 | Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study |
| Q36664112 | Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial |
| Q84685736 | Metabolic syndrome in patients with schizophrenia: CATIE results |
| Q37129646 | Metabolic syndrome in people with schizophrenia: a review. |
| Q45040992 | Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics |
| Q51366559 | Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India. |
| Q34616707 | Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions |
| Q37822216 | Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs |
| Q39888640 | Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. |
| Q36893286 | Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia |
| Q31077469 | Missing clinical and behavioral health data in a large electronic health record (EHR) system |
| Q37678423 | Modifying the risk of atypical antipsychotics in the treatment of juvenile-onset schizophrenia |
| Q47575503 | Monitoring and Treating Metabolic Abnormalities in Patients with Early Psychosis Initiated on Antipsychotic Medications |
| Q28275063 | Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients |
| Q37089323 | Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study |
| Q50703449 | Monitoring metabolic side effects of atypical antipsychotics in people with an intellectual disability. |
| Q50044596 | Monitoring of Metabolic Adverse Effects Associated With Atypical Antipsychotics Use in an Outpatient Psychiatric Clinic |
| Q48015522 | Monitoring of Recommended Metabolic Laboratory Parameters Among Medicaid Recipients on Second-Generation Antipsychotics in Federally Qualified Health Centers |
| Q47344131 | Naturalistic impact of second-generation antipsychotics on weight gain |
| Q64244211 | Need for Cardiovascular Risk Reduction in Persons With Serious Mental Illness: Design of a Comprehensive Intervention |
| Q36929705 | New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania |
| Q42578814 | Non-HDL Cholesterol: A New Endpoint in Cardio-Metabolic Health Monitoring |
| Q34314781 | Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio. |
| Q35074667 | Obesity and coronary risk in patients treated with second-generation antipsychotics |
| Q51902723 | Obesity and metabolic syndrome in a psychiatric rehabilitation service. |
| Q47136605 | Obesity in individuals with schizophrenia: a case controlled study in Scotland |
| Q37788449 | Observations in psychotropic medication usage in patients with behavior disorders presenting to a specialty clinic. |
| Q45326738 | Off-Label Prescribing of Second-Generation Antipsychotics to Elderly Veterans with Posttraumatic Stress Disorder and Dementia |
| Q37252495 | Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues |
| Q40380108 | Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. |
| Q40501461 | Olanzapine in bipolar disorder |
| Q46680030 | Olanzapine metabolic side effects: a weight gain issue? |
| Q47336832 | Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats |
| Q36511290 | Olanzapine: a 5-year perspective |
| Q37885980 | Oral paliperidone: a review of its use in the management of schizoaffective disorder |
| Q89330644 | Overcoming barriers to monitoring patients taking second-generation antipsychotics |
| Q37766850 | Paliperidone extended release: a review of its use in the management of schizophrenia |
| Q37285348 | Pancreatitis and diabetic ketoacidosis with quetiapine use |
| Q38829604 | Participative mental health consumer research for improving physical health care: An integrative review |
| Q34726953 | Past and Present Progress in the Pharmacologic Treatment of Schizophrenia |
| Q38584848 | Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses |
| Q64332771 | Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics |
| Q58162307 | Perceptions of Overall Health and Recency of Screenings |
| Q23915526 | Perceptions of barriers and benefits to physical activity among outpatients in psychiatric rehabilitation |
| Q47337805 | Performance of a weight-related measure of Quality of Life in a psychiatric sample |
| Q30371570 | Perspectives of Overweight Latinos with Serious Mental Illness on Barriers and Facilitators to Health Behavior Change. |
| Q37220366 | Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications |
| Q38072081 | Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression |
| Q24194410 | Pharmacological interventions for reducing weight gain in schizophrenia |
| Q27692023 | Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis |
| Q34691376 | Pharmacological treatment of ambulatory schizophrenic patients in Belgium |
| Q36729609 | Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach? |
| Q37742068 | Pharmacotherapy of bipolar disorder in children and adolescents: recent progress |
| Q38132160 | Physical complications in early clozapine treatment: a case report and implications for safe monitoring |
| Q37771647 | Physical health in schizophrenia: a challenge for antipsychotic therapy |
| Q37771645 | Physical health management in psychiatric settings |
| Q34623350 | Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. |
| Q35016170 | Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. |
| Q35011992 | Physician patterns of metabolic screening for patients taking atypical antipsychotics: a retrospective database study |
| Q40255006 | Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients |
| Q36895526 | Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI. |
| Q43982988 | Poor health behaviour and reduced quality of life of people treated with psychotropic drugs |
| Q37671706 | Post-traumatic stress disorder (PTSD) is not a contraindication to gastric bypass in veterans with morbid obesity |
| Q34795118 | Posttraumatic stress disorder in male military veterans with comorbid overweight and obesity: psychotropic, antihypertensive, and metabolic medications |
| Q89841227 | Pragmatic trial design of an intervention to reduce cardiovascular risk in people with serious mental illness |
| Q36756538 | Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting |
| Q33835476 | Predictors of mortality in patients with serious mental illness and co-occurring type 2 diabetes |
| Q47631621 | Preparing the workforce for integrated healthcare: A systematic review |
| Q34181934 | Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review |
| Q34944648 | Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study |
| Q35251956 | Prevalence of metabolic syndrome in a predominantly cuban, psychiatrically ill, and homeless population |
| Q35834883 | Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a German observational study |
| Q45249093 | Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study |
| Q50749933 | Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. |
| Q50947814 | Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents--a cross-sectional study. |
| Q31097538 | Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism |
| Q37196084 | Preventive counseling for chronic disease: missed opportunities in a community mental health center |
| Q89498733 | Primary Care Quality Improvement Metrics and National Committee on Quality Assurance Medical Home Recognition for Children With Medical Complexity |
| Q37191101 | Primary care providers' views on metabolic monitoring of outpatients taking antipsychotic medication |
| Q38469831 | Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care. |
| Q28487733 | Propensity score estimation to address calendar time-specific channeling in comparative effectiveness research of second generation antipsychotics |
| Q35763638 | Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice |
| Q27012600 | Psychological and psychiatric aspects of treatment of obesity and nonalcoholic fatty liver disease |
| Q37333831 | Psychological conditions in adults with diabetes. |
| Q37422575 | Psychopharmacology in psychodermatology |
| Q61451347 | Psychopharmaka und Diabetes |
| Q38374033 | Psychotherapy Alone and Combined With Medication as Treatments for Bipolar II Depression: A Randomized Controlled Trial |
| Q40119718 | Psychotic disorder is an independent risk factor for increased fasting glucose and waist circumference |
| Q33498169 | Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells |
| Q40897841 | Psychotropic medicine prescriptions in Italian youths: a multiregional study. |
| Q37892448 | Quality assessment of physical activity recommendations within clinical practice guidelines for the prevention and treatment of cardio-metabolic risk factors in people with schizophrenia |
| Q36282556 | Quality improvement in resident education: a pilot project to mitigate metabolic side effects from atypical antipsychotic medications in youth |
| Q34681144 | Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior? |
| Q38188744 | Quetiapine for insomnia: A review of the literature. |
| Q41962668 | Quetiapine-associated pancreatitis in a geriatric critical care patient with delirium |
| Q36316977 | Quetiapine: a review of its use in acute mania and depression associated with bipolar disorder |
| Q36611362 | Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia |
| Q34130763 | Randomized controlled trial to assess reduction of cardiovascular disease risk in patients with bipolar disorder: the Self-Management Addressing Heart Risk Trial (SMAHRT) |
| Q92046656 | Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia |
| Q40457990 | Real-world risk of diabetes with antipsychotic use in older New Zealanders: a case-crossover study. |
| Q38853963 | Reducing cardiovascular risk factors in non-selected outpatients with schizophrenia |
| Q41587365 | Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia |
| Q33862577 | Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents |
| Q36836820 | Relationship between obesity and antipsychotic drug use in the adult population: a longitudinal, retrospective claim database study in Primary Care settings |
| Q33483929 | Results of a longitudinal analysis of national data to examine relationships between organizational and market characteristics and changes in antipsychotic prescribing in US nursing homes from 1996 through 2006. |
| Q36883316 | Rethinking antipsychotic formulary policy |
| Q36219618 | Retrospective study of Japanese patients with schizophrenia treated with aripiprazole |
| Q92897789 | Reverse Integration Initiatives for Individuals With Serious Mental Illness |
| Q24657398 | Review of olanzapine in the management of bipolar disorders |
| Q36836750 | Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia |
| Q34595255 | Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study |
| Q34659165 | Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database |
| Q36929181 | Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. |
| Q36106798 | Risperidone for bipolar disorders |
| Q50302665 | Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. |
| Q37165588 | Risperidone in the treatment of bipolar mania |
| Q37756971 | Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder |
| Q55078542 | Risperidone-induced type 2 diabetes presenting with diabetic ketoacidosis. |
| Q36133830 | Risperidone: a review of its use in the treatment of bipolar mania |
| Q36688973 | Role of aripiprazole in treating mood disorders |
| Q36473542 | Role of risperidone in children with autism spectrum disorder |
| Q37296552 | Roles in and barriers to metabolic screening for people taking antipsychotic medications: a survey of psychiatrists |
| Q34680925 | Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. |
| Q90600019 | Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: a cross-sectional study |
| Q37495004 | SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. |
| Q35001376 | STRIDE: a randomized trial of a lifestyle intervention to promote weight loss among individuals taking antipsychotic medications |
| Q33587032 | Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). |
| Q88516633 | Schizophrenia and metabolic dysregulation: shared roots? |
| Q37226376 | Schizophrenia, obesity, and antipsychotic medications: what can we do? |
| Q51921937 | Schizophrenia: multi-attribute utility theory approach to selection of atypical antipsychotics. |
| Q39931627 | Screening for Metabolic Syndrome in Mental Health Consumers Using an Electronic Metabolic Monitoring Form |
| Q35222921 | Screening for cardiovascular risk factors in adults with serious mental illness: a review of the evidence |
| Q53385226 | Screening for diabetes in patients receiving second-generation atypical antipsychotics. |
| Q33890480 | Screening for diabetes using Japanese monitoring guidance in schizophrenia patients treated with second-generation antipsychotics: a cross-sectional study using baseline data |
| Q34376884 | Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor |
| Q39027972 | Second-Generation Antipsychotic Utilization and Metabolic Parameter Monitoring in an Inpatient Pediatric Population: A Retrospective Analysis |
| Q33988376 | Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review |
| Q61943520 | Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome |
| Q81813015 | Second-generation antipsychotics and the metabolic syndrome |
| Q36523265 | Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? |
| Q38633456 | Serious mental illness and medical comorbidities: Findings from an integrated health care system |
| Q39039470 | Serotonin improves glucose metabolism by Serotonylation of the small GTPase Rab4 in L6 skeletal muscle cells |
| Q33802927 | Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders |
| Q39640688 | Sex Differences in Weight Loss among Veterans with Serious Mental Illness: Observational Study of a National Weight Management Program. |
| Q24642721 | Side effects of atypical antipsychotics: a brief overview |
| Q44387572 | Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists |
| Q91643643 | Small-intestinal necrosis due to non-occlusive mesenteric ischemia with diabetic ketoacidosis after quetiapine treatment |
| Q58117665 | Solutions for Wellness: Results of a Manualized Psychoeducational Program for Adults with Psychiatric Disorders |
| Q35936870 | Starting clozapine in the community: a UK perspective |
| Q37793086 | Statistically Significant Increase in Weight Caused by Low‐Dose Quetiapine |
| Q80501614 | Stimulation of glycogen synthesis and inactivation of phosphorylase in hepatocytes by serotonergic mechanisms, and counter-regulation by atypical antipsychotic drugs |
| Q33985405 | Strategies for monitoring outcomes in patients with bipolar disorder |
| Q34564212 | Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II |
| Q38352080 | Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists |
| Q36276541 | Switching antipsychotics: an updated review with a focus on quetiapine |
| Q42615483 | Switching to ziprasidone in the clinical practice setting: an open-label study |
| Q36626242 | Symptom domains of schizophrenia: the role of atypical antipsychotic agents |
| Q37137008 | Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem |
| Q89495962 | THE METABOLIC SYNDROME IN OUTPATIENTS WITH PSYCHOSIS: A COMPARATIVE STUDY BETWEEN LONG ACTING INJECTABLE OLANZAPINE AND RISPERIDONE |
| Q38260282 | Telemedicine as a tool to mitigate cardiometabolic risk associated with serious mental illness |
| Q37790906 | The Adjunctive Use of Metformin to Treat or Prevent Atypical Antipsychotic-Induced Weight Gain: A Review |
| Q47642128 | The Black Book of Psychotropic Dosing and Monitoring |
| Q54959460 | The Influence of Metabolic Syndrome and Sex on the DNA Methylome in Schizophrenia. |
| Q36431011 | The Role of Clinical Setting and Management Approach in Metabolic Testing Among Youths and Adults Treated With Antipsychotics |
| Q34807210 | The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial |
| Q33950877 | The appropriateness of routine medication treatment for schizophrenia. |
| Q34143764 | The effectiveness of specialist roles in mental health metabolic monitoring: a retrospective cross-sectional comparison study. |
| Q38170310 | The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity |
| Q37408274 | The impact of a pharmacist assisted clinic upon medication adherence and quality of life in mental health patients |
| Q52653617 | The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression. |
| Q53827546 | The lesser of two evils: a qualitative study of quetiapine prescribing by family physicians. |
| Q36577856 | The metabolic effects of antipsychotic medications |
| Q37771646 | The need for routine physical health care in schizophrenia |
| Q50658512 | The prevalence of metabolic syndrome in people with severe mental illness: a mediation analysis. |
| Q46079253 | The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness |
| Q35930948 | The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning |
| Q36626251 | The relationship between patient satisfaction and treatment outcomes in schizophrenia |
| Q36463221 | The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities |
| Q53383892 | The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study. |
| Q36979293 | The use of antipsychotics in children and adolescents with bipolar disorders |
| Q46525813 | To: Mackin P, Watkinson HM, Young AH (2005) Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48:215-221. |
| Q37030481 | Translation of the diabetes prevention program into a community mental health organization for individuals with severe mental illness: a case study |
| Q45099753 | Treating the mind and body in schizophrenia: risks and prevention. |
| Q41528294 | Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole |
| Q37612706 | Treatment of bipolar disorders and metabolic syndrome: implications for primary care |
| Q37889896 | Treatment of co-morbid mental illness in primary care: how to minimize weight gain, diabetes, and metabolic syndrome |
| Q38808579 | Treatment options for the management of pervasive developmental disorders |
| Q38530458 | Type 2 diabetes in children and adolescents on atypical antipsychotics |
| Q45064639 | UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). |
| Q58201746 | Understanding antipsychotic-induced weight gain and other metabolic issues |
| Q37896627 | Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option? |
| Q35994346 | Use of an electronic metabolic monitoring form in a mental health service - a retrospective file audit |
| Q38290683 | Use of aripiprazole for delirium in the elderly: a short review |
| Q37356486 | Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness |
| Q37721692 | Using Routine Hemoglobin A1c Testing to Determine the Glycemic Status in Psychiatric Inpatients. |
| Q93112073 | Utilization of somatic healthcare in Croatian patients with schizophrenia spectrum disorder, major depression, PTSD and the general population |
| Q47141502 | Utilization of the Behavior Change Wheel framework to develop a model to improve cardiometabolic screening for people with severe mental illness |
| Q35011987 | Variables associated with general practitioners' knowledge about and diagnostic skills for schizophrenia |
| Q34054063 | Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine. |
| Q38151453 | Weight considerations in psychotropic drug prescribing and switching |
| Q42169005 | Weight development in patients treated with risperidone: a 5-year naturalistic study |
| Q37865505 | Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. |
| Q34033259 | Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians |
| Q37273061 | Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents |
| Q37067704 | Weight gain and metabolic issues of medicines used for bipolar disorder |
| Q37865068 | Weight gain associated with taking psychotropic medication: an integrative review |
| Q34557537 | Weight gain, obesity, and psychotropic prescribing |
| Q36883728 | Weight loss intervention for people with serious mental illness: a randomized controlled trial of the RENEW program |
| Q38121916 | What makes a difference to patients? |
| Q27014860 | When to start aripiprazole therapy in patients with bipolar mania |
| Q46142884 | World Congress on the Insulin Resistance Syndrome, 2009: Insulin resistance mechanisms, the brain, and insulin resistance in youth and in the polycystic ovary syndrome |
| Q36938311 | Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder |
| Q83866936 | Ziprasidone in bipolar disorder |
| Q36289437 | Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review |
| Q42227533 | Ziprasidone therapy in elderly patients with psychotic mood disorders and Parkinson's disease |
| Q79776053 | [Antipsychotic drug-induced changes in metabolism] |
| Q86538328 | [Cardiac and metabolic risk factors in severe mental disorders. Task of a prevention manager] |
| Q80737324 | [Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics] |
| Q83130945 | [Metabolic disorders under antipsychotic treatment] |
| Q83164710 | [Perception of atypical antipsychotics' side effects through speech analysis of schizophrenic patients. TALK Study] |
| Q79327220 | [Pharmacotherapy for schizophrenia] |
| Q87422834 | [Psychopharmacotherapy in patients with cardiovascular diseases] |
Search more.